Get started
Author

Ying Chi

Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial
2022 · Feng Xue, Huiyuan Li, et al. · The Lancet Haematology · 81
A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia
2024 · Yunfei Chen, Yanmei Xu, et al. · New England Journal of Medicine · 57
Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial
2024 · Yunfei Chen, Yanmei Xu, et al. · Signal Transduction and Targeted Therapy · 34
PDF
Prediction of thrombosis in polycythemia vera: Development and validation of a multiple factor-based prognostic score system
2023 · Wenjing Gu, Yuhui Zhang, et al. · Research and Practice in Thrombosis and Haemostasis · 19
Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial
2025 · Yunfei Chen, Yanmei Xu, et al. · BMJ · 10
PDF
Machine learning analyses constructed a novel model to predict recurrent thrombosis in adults with essential thrombocythemia
2023 · Jia Chen, Huan Dong, et al. · Journal of Thrombosis and Thrombolysis · 9
Proteomics landscape and machine learning prediction of long‐term response to splenectomy in primary immune thrombocytopenia
2024 · Ting Sun, Jia Chen, et al. · British Journal of Haematology · 8
PDF
Increased reactive oxygen species lead to overactivation of platelets in essential thrombocythemia
2023 · Huan Dong, Huiyuan Li, et al. · Thrombosis Research · 8
Risk factors for inhibitors in hemophilia A based on RNA‐seq and DNA methylation
2022 · Wei Liu, Cuicui Lyu, et al. · Research and Practice in Thrombosis and Haemostasis · 8
Genetically determined telomere length and risk for haematologic diseases: results from large prospective cohorts and Mendelian Randomization analysis
2024 · Yang Li, Jia Chen, et al. · Blood Cancer Journal · 5
PDF
Phase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity
2026 · Wei Liu, Xiaolei Pei, et al. · Signal Transduction and Targeted Therapy · 4
PDF
Childhood and adolescent essential thrombocythemia and prefibrotic primary myelofibrosis: insights into diagnosis, outcomes, and treatment from a large Chinese cohort
2024 · Rongfeng Fu, Huan Dong, et al. · Leukemia · 4
Integrating chemokines and machine learning algorithms for diagnosis and bleeding assessment in primary immune thrombocytopenia: A prospective cohort study
2024 · Qing Wen, Ting Sun, et al. · British Journal of Haematology · 4
PDF
Th17-driven CD8+ T cells in hUC-MSC and CAR T-cell dual immunotherapy for superior anti-tumor efficacy
2026 · Caidong Hu, Haixiao Zhang, et al. · Cell Death and Disease · 3
PDF
Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial
2026 · Yunfei Chen, Zhengjie Hua, et al. · EClinicalMedicine · 3
Reduced Platelet Activation in Triple-Negative Essential Thrombocythemia Compared with JAK2V617F -Mutated Essential Thrombocythemia
2024 · Huan Dong, Jia Chen, et al. · Clinical Cancer Research · 3
Sex-specific impact on disease outcome and the mutational landscape in essential thrombocythemia: A retrospective cohort study
2024 · Jia Chen, Huan Dong, et al. · Chinese Medical Journal · 3
Molecular analysis of phenotypic heterogeneity in JAK2V617F ‐positive myeloproliferative neoplasms reveals a potential target for therapy
2023 · Wenjing Gu, Jingyuan Tong, et al. · British Journal of Haematology · 3
IFNα2b modulates anti-tumor immune responses involving STAT3-associated dendritic cell dysfunction in JAK2v617f-positive myeloproliferative neoplasms
2026 · Lijun Fang, Rongfeng Fu, et al. · Drug Resistance Updates · 2
Prophylactic Administration of Glucocorticoids and Tacrolimus in AAV8-F8 Gene Therapy of Severe Haemophilia-a Achieved a Significant Long-Term Efficacy
2024 · Wei Liu, Xiaolei Pei, et al. · Blood · 2
PDF
Efficacy and Safety of Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Immune Thrombocytopenia: A Prospective, Single Centre, Single Arm, Phase I Trial
2023 · Yunfei Chen, Xu Yanmei, et al. · Blood · 2
Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura
2026 · Qing Wen, Jia Chen, et al. · Journal of Thrombosis and Haemostasis · 1
Multi-Omics Analysis of Human Mesenchymal Stem Cell Guides Perinatal MSC Based Cellular Therapy for Splenectomy-Nonresponsive Refractory Immune Thrombocytopenia: A Phase I Clinical Trial
2022 · Yuchen Gao, Ying Chi, et al. · Blood · 1
Sequence-based artificial intelligence-guided inhibitory peptides to counteract AAV neutralizing antibodies in gene therapy.
2026 · Bingqi Xu, Xin Zhang, et al. · PubMed
PDF
Identification of key biomarkers for initial corticosteroid resistance in newly diagnosed primary immune thrombocytopenia
2026 · Yanming Wang, Jia Chen, et al. · Experimental Hematology
Works count: 39
Citation count: 274
H-index: 8
I10-index: 5
Year
Topic
Type